4/A: ProQR Therapeutics Director Adjusts Stock Option Filing
Insider Transaction Amendment
ProQR Therapeutics N.V. files an amended Form 4 to correct the number of share options reported for Director Gylvin Lykke Hinsch.
Summary
- This filing is an amendment (Form 4/A) to a previously filed Form 4 by Gylvin Lykke Hinsch, a Director at ProQR Therapeutics N.V.
- The amendment corrects the number of share options reported in the original filing.
- No other information from the original Form 4 has been changed.
- The transaction date for the earliest transaction is June 2, 2026.
- The reporting person is Gylvin Lykke Hinsch, who is a Director and holds no other specified insider roles.
- The filing indicates a 10b5-1(c) plan is in place for transactions.
Sentiment
Score: 2
Explanation: StockSavvy.ai views this as a low-impact filing due to its nature as a technical amendment correcting a previous disclosure, with no new material information provided.
Future Outlook
The filing does not contain forward-looking statements or guidance.
Industry Context
StockSavvy.ai notes that this filing is a routine administrative amendment to an insider transaction report, correcting a numerical detail. Such amendments are common and typically do not reflect new strategic information or material changes in the company's performance.
Stakeholder Impact
- Shareholders: Minimal impact, as this is a correction of a prior filing and does not introduce new material information about the company's operations or financial health.
Key Dates
| Date | Description |
|---|---|
| 06/01/2026 | Date used to determine the closing market price for the Issuer's ordinary shares for the reported option price. |
| 06/02/2026 | Earliest transaction date reported in the filing. |
| 06/02/2026 | Transaction date for the share option. |
| 06/03/2026 | Date of the original Form 4 filing that is being amended. |
| 06/30/2026 | Signature date of the amended Form 4/A. |
| 06/01/2036 | Expiration date of the share option. |
| 06/02/2027 | Initial vesting date for 25% of the shares subject to the option. |
Keywords
SEC Form 4/A, ProQR Therapeutics, Insider Trading, Stock Options, Director Filing, Beneficial Ownership, Securities Exchange Act
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.